In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid

International Journal of Pharmaceutics

Volumn 444, Issue 1-2, 2013, Pages 10-17

  Booysen, L L I J ^a,b   Kalombo, L ^a   Brooks, E ^c   Hansen, R ^c   Gilliland, J ^c   Gruppo, V ^c   Lungenhofer, P ^c   Semete Makokotlela, B ^a   Swai, H S ^a   Kotze, A F ^b   Lenaerts, A ^c   Du Plessis, L H ^b  

^a DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

In vitro; In vivo; Isoniazid; PEG coated; Pharmacodynamic; Pharmacokinetic; PLGA nanoparticles; Rifampicin

Indexed keywords

ISONIAZID; MACROGOL; NANOPARTICLE; POLYGLACTIN; POLYGLACTIN NANOPARTICLE; POLYMER; PROTEIN; RIFAMPICIN; SOLVENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG PROTEIN BINDING; EMULSION; EVAPORATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIVER; LUNG; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SPRAY DRYING; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; ISONIAZID; LACTIC ACID; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; RIFAMPIN;

EID: 84873733393     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.01.038     Document Type: Article

References (37)

1. P. Aggarwal, J.B. Hall, C.B. McLeland, M.A. Dobrovolskaia, and S.E. McNeil Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy Adv. Drug Deliv. Rev. 61 2009 428 437
2. Z. Ahmad, R. Pandey, S. Sharma, and G.K. Khuller Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles Int. J. Ant. Agents 31 2008 142 146
3. Z. Ahmad, R. Pandey, S. Sharma, and G.K. Khuller Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses Int. J. Ant. Agents 27 2006 409 416
4. S. Azarmi, W.H. Roa, and R. Löbenberg Targeted delivery of nanoparticles for the treatment of lung diseases Adv. Drug Deliv. Rev. 60 2008 863 875
5. D. Benator, M. Bhattacharya, L. Bozeman, W. Burman, A. Cantazaro, R. Chaisson, F. Gordin, C.R. Horsburgh, J. Horton, A. Khan, C. Lahart, B. Metchock, C. Pachucki, L. Stanton, A. Vernon, M.E. Villarino, Y.C. Wang, M. Weiner, and S. Weis Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial The Lancet 360 2002 528 534
6. J.V. Brooks, and I.M. Orme Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model Antimicrob. Agents Chemother 42 1998 3047 3048
7. N.R. Budha, R.E. Lee, and B. Meibohm Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs Curr. Med. Chem. 15 2008 809 825
8. D.C. Carter, X.M. He, S.H. Munson, P.D. Twigg, K.M. Gernert, M.B. Broom, and T.Y. Miller Three-dimensional structure of human serum albumin Science 244 1989 1195 1198
9. T. Cedervall, I. Lynch, M. Foy, T. Berggård, S. Donnelly, G. Cagney, S. Linse, and K. Dawson Detailed identification of plasma proteins adsorbed on copolymer nanoparticles Angewandte Chemie 119 2007 5856 5858
10. P. Couvreur, and C. Vauthier Nanotechnology: intelligent design to treat complex disease Pharm. Res. 23 2006 1417 1450
11. F. Cui, F. Qian, and C. Yin Preparation and characterization of mucoadhesive polymer-coated nanoparticles Int. J. Pharm. 316 2006 154 161
12. J. Dhillon, and D.A. Mitchison Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages Am. J. Respir. Crit. Care Med. 145 1992 212 214
13. G.A. Ellard The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency Int. J. Tuberc. Lung Dis. 3 1999 S322 S324
14. H. Epstein, D. Gutman, E. Cohen-Sela, E. Haber, O. Elmalak, N. Koroukhov, H. Danenberg, and G. Golomb Preparation of alendronate liposomes for enhanced stability and bioactivity: in vitro and in vivo characterization AAPS J. 10 2008 505 515
15. J. Grosset, and S. Leventis Adverse effects of rifampicin Rev. Infect. Dis. 5 1983 S440 S450
16. V. Gruppo, C.M. Johnson, K.S. Marietta, H. Scherman, E.E. Zink, D.C. Crick, L.B. Adams, I.M. Orme, and A.J. Lenaerts Rapid microbiologic and pharmacologic evaluation of experimental compounds against mycobacterium tuberculosis Antimicrob. Agents Chemother 50 2006 1245 1250
17. P. Gurumurthy, G. Ramachandran, S. Vijayalakshmi, A.K. Hemanth Kumar, P. Venkatesan, V. Chandrasekaran, V. Vjayasekaran, V. Kumaraswami, and R. Prabhakar Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics Int. J. Tuberc. Lung Dis. 3 1999 119 125
18. R.A. Jain The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices Biomaterials 21 2000 2475 2490
19. Kalombo, L. 2008. Nanoparticle carriers for Drug Administration. Patent 2469965.
20. J. Kingsley, H. Dou, J. Morehead, B. Rabinow, H. Gendelman, and C. Destache Nanotechnology: a focus on nanoparticles as a drug delivery system J. Neuroimmune Pharmacol. 1 2006 340 350
21. K.O. Kisich, S. Gelperina, M.P. Higgins, S. Wilson, E. Shipulo, E. Oganesyan, and L. Heifets Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis Int. J. Pharm. 345 2007 154 162
22. G. Ledet, and T.K. Mandal Nanomedicine: emerging therapeutics for the 21st century US Pharm. 37 2012 7 11
23. S.D. Li, and L. Huang Pharmacokinetics and biodistribution of nanoparticles Mol. Pharm. 5 2008 496 504
24. N. Maggi, C.R. Pasqualucci, R. Ballotta, and P. Sensi Rifampicin: a new orally active rifamycin Chemotherapy 11 1966 285 292
25. H. McIlleron, P. Wash, A. Burger, J. Norman, P.I. Folb, and P. Smith Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients Antimicrob. Agents Chemother. 50 2006 1170 1177
26. M. Nawaz Bioavailability and disposition kinetics of rifampicin capsules Pakistan Journal of Pharmaceutical Sciences 1 1988 29 35
27. R. Panchagnula, and S. Agrawal Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin Int. J. Pharm. 271 2004 1 4
28. J.W. Pape, S.S. Jean, J.L. Ho, A. Hafner, and W.D. Johnson Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection The Lancet 342 1993 268 272
29. B. Semete, L.I.J. Booysen, L. Kalombo, J.D. Venter, L. Katata, B. Ramalapa, J.A. Verschoor, and H. Swai In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles Toxicol. Appl. Pharmacol. 249 2010 158 165
30. B. Semete, L. Booysen, L. Kalombo, B. Ramalapa, R. Hayeshi, and H.S. Swai Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration Int. J. Pharm. 424 2012 115 120
31. B. Semete, L. Booysen, Y. Lemmer, L. Kalombo, L. Katata, J. Verschoor, and H.S. Swai In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems Nanomed Nanotech. Biol. Med. 6 2010 662 671
32. S. Stolnik, B. Daudali, A. Arien, J. Whetstone, C.R. Heald, M.C. Garnett, S.S. Davis, and L. Illum The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers Biochim. Biophys. Acta 1514 2001 261 279
33. K. Takayama, L. Wang, and H.L. David Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2 1972 29 35
34. H. Takeuchi, Y. Matsui, H. Sugihara, H. Yamamoto, Y. Kawashima, and J. Thongborisute Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems Adv. Drug Deliv. Rev. 57 2005 1583 1594
35. R.J. Wallace, D.R. Nash, L.C. Steele, and V. Steingrube Susceptability testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth J Clin Microbiol. 24 1986 976 981
36. World Health Organization (WHO) Global Tuberculosis Report 2012. WHO Library Cataloguing-in-Publication Data 2012 WHO Press Geneva, Switzerland
37. J. Woo, W. Cheung, R. Chan, S. Chan, A. Cheng, and K. Chan In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and [alpha]-1-acid glycoprotein Clin. Biochem. 29 1996 175 177